Clovis Oncology, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$60.2M
Doctors Paid
5,715
Transactions
29,736
2022 Total
$7.0M
Payment Breakdown by Category
Research$53.7M (89.3%)
Consulting$1.4M (2.3%)
Travel$634,986 (1.1%)
Food & Beverage$473,775 (0.8%)
Royalty/License$16,250 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $53.7M | 8,702 | 89.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.3M | 749 | 3.8% |
| Consulting Fee | $1.4M | 596 | 2.3% |
| Current or prospective ownership or investment interest | $1.1M | 14 | 1.9% |
| Travel and Lodging | $634,986 | 1,468 | 1.1% |
| Food and Beverage | $473,775 | 16,780 | 0.8% |
| Grant | $350,000 | 6 | 0.6% |
| Space rental or facility fees (teaching hospital only) | $132,225 | 49 | 0.2% |
| Education | $33,102 | 1,370 | 0.1% |
| Royalty or License | $16,250 | 1 | 0.0% |
| Honoraria | $535.00 | 1 | 0.0% |
Payments by Type
Research
$53.7M
8,702 transactions
General
$6.5M
21,034 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | $11.1M | 0 | 1,483 |
| A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | $6.5M | 1 | 1,126 |
| A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON2) | $5.9M | 0 | 1,394 |
| A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | $4.9M | 0 | 318 |
| Lung MAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer Sub-Study S1900A A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA 1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer | $4.0M | 0 | 9 |
| Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS) | $2.6M | 0 | 425 |
| A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes (LODESTAR) | $2.6M | 0 | 308 |
| A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (ARIEL3) | $1.8M | 0 | 1,335 |
| A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) | $1.6M | 0 | 139 |
| Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients | $1.4M | 0 | 66 |
| A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) | $1.1M | 0 | 54 |
| A Phase II, randomized, double-blind, study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer | $870,041 | 0 | 5 |
| FAP Imaging: Imaging of Solid Tumors Using 68Ga-FAP-2286 | $812,961 | 0 | 8 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) | $744,269 | 1 | 749 |
| A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer | $532,954 | 0 | 266 |
| A PHASE 2, OPEN LABEL STUDY OF MAINTENANCE RUCAPARIB IN PATIENTS WITH PLATINUM-SENSITIVE ADVANCED PANCREATIC CANCER AND A KNOWN DELETERIOUS GERMLINE OR SOMATIC BRCA1/2 OR PALB2 MUTATION | $522,631 | 0 | 2 |
| A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2) (ARIEL2) | $473,920 | 1 | 377 |
| A Phase 3, Open-Label, Multicenter, Randomized Study of Oral CO 1686 Versus Single Agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non Small Cell Lung Cancer (NSCLC) after Failure of At Least One Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI). | $452,343 | 0 | 72 |
| Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP) | $450,033 | 0 | 201 |
| A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients with an Advanced Solid Tumor | $445,739 | 0 | 11 |
| A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3) | $367,956 | 0 | 82 |
| A Phase II study with a safety lead-in of nivolumab in combination with bevacizumab or in combination with bevacizumab and rucaparib for the treatment of relapsed epithelial ovarian, fallopian tube or peritoneal cancer | $336,674 | 0 | 3 |
| A Randomized, Open-Label, Phase II Stud of CO-1686 or Erlotinib as First-Line Treatment of Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) | $328,278 | 0 | 98 |
| Phase 1: Rucaparib and postoperative Radiotherapy in triple negative breast cancer | $287,680 | 0 | 3 |
| Phase 2: Single agent rucaparib in metastatic/locally advanced pancreatic cancer | $243,686 | 0 | 5 |
| A Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES) | $240,049 | 1 | 44 |
| A Phase I Study of Rucaparib Administered Concurrently with Postoperative Radiotherapy in Patients with Triple Negative Breast Cancer with an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy | $230,144 | 0 | 2 |
| ENDOBARR: An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma | $213,972 | 0 | 2 |
| ENDOBARR An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma | $187,226 | 0 | 2 |
| A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II) | $154,730 | 0 | 21 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Kimberly Resnick, M.d, M.D | Hospice and Palliative Medicine | Cleveland, OH | $54,252 | $0 |
| Robert Coleman, M.d, M.D | Gynecologic Oncology | Houston, TX | $54,073 | $0 |
| Mark Hunter, M.d, M.D | Gynecologic Oncology | Columbia, MO | $53,089 | $0 |
| Dr. David Mutch, Md, MD | Gynecologic Oncology | Saint Louis, MO | $52,029 | $0 |
| Robert Holloway, Md, MD | Gynecologic Oncology | Orlando, FL | $50,866 | $0 |
| Dr. Edward Kost, M.d, M.D | Obstetrics & Gynecology | San Antonio, TX | $47,121 | $0 |
| Rodney Rocconi, Md, MD | Gynecologic Oncology | Jackson, MS | $45,732 | $0 |
| Gottfried Konecny, Md, MD | Internal Medicine | Los Angeles, CA | $43,932 | $0 |
| Dr. Matthew Powell, Md, MD | Gynecologic Oncology | Saint Louis, MO | $41,671 | $0 |
| Dr. Beverly Ortiz, M.d., F.a.c.o.g.,, M.D., F.A.C.O.G., | Gynecologic Oncology | Riverhead, NY | $40,056 | $0 |
| Joseph Readling, Md, MD | Hematology & Oncology | Binghamton, NY | $39,501 | $0 |
| Neil Rosenshein, Md, MD | Gynecologic Oncology | Baltimore, MD | $36,027 | $0 |
| Thomas Herzog, M.d, M.D | Gynecologic Oncology | Cincinnati, OH | $33,956 | $0 |
| Dr. Rabbie Hanna, M.d, M.D | Obstetrics & Gynecology | Detroit, MI | $33,389 | $0 |
| Dr. Richard Drake, Md, MD | Obstetrics & Gynecology | The Woodlands, TX | $31,806 | $0 |
| Nicholas Vogelzang, Md, MD | Hematology & Oncology | Las Vegas, NV | $31,139 | $0 |
| Jubilee Brown, Md, MD | Obstetrics & Gynecology | Charlotte, NC | $29,078 | $0 |
| Shruti Trehan, Md, MD | Hematology & Oncology | Canton, OH | $27,133 | $0 |
| Thomas Heffernan, Md, MD | Obstetrics & Gynecology | Dallas, TX | $26,836 | $0 |
| Mr. Ruemu Birhiray, Md, MD | Hematology & Oncology | Indianapolis, IN | $26,693 | $0 |
| David O'malley, M.d, M.D | Gynecologic Oncology | Hilliard, OH | $26,377 | $0 |
| Hope Cottrill, Md, MD | Medical Oncology | Lexington, KY | $25,088 | $0 |
| David Miller, Md, MD | Gynecologic Oncology | Dallas, TX | $24,329 | $0 |
| Dr. Michael Birrer, M.d. Ph.d, M.D. PH.D | Hematology & Oncology | Birmingham, AL | $23,555 | $0 |
| Kenneth Kernen, Md, MD | Urology | Troy, MI | $21,967 | $0 |
About Clovis Oncology, Inc.
Clovis Oncology, Inc. has made $60.2M in payments to 5,715 healthcare providers, recorded across 29,736 transactions in the CMS Open Payments database. In 2022, the company paid $7.0M. The top product by payment volume is Rubraca ($44.5M).
Payments were distributed across 106 medical specialties. The top specialty by payment amount is Gynecologic Oncology ($2.1M to 476 doctors).
Payment categories include: Food & Beverage ($473,775), Consulting ($1.4M), Research ($53.7M), Travel & Lodging ($634,986), Royalties ($16,250).
Clovis Oncology, Inc. is associated with 6 products in the CMS Open Payments database, including Rubraca, RUBRACA, and Rociletinib.